|
Delaware
|
|
2836
|
|
52-0845822
|
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(Primary
Standard Industrial
Classification
Code Number)
|
|
(I.R.S.
Employer
Identification
Number)
|
|
2.1
|
First
Asset Purchase Agreement dated March 11, 2003, by and between the
Company
and ISI.(1)
|
|
2.2
|
Second
Asset Purchase Agreement dated March 11, 2003, by and between the
Company
and ISI.(1)
|
|
3.1
|
Amended
and Restated Certificate of Incorporation of the Company, as amended,
along with Certificates of Designations.
|
|
3.1.1
|
Series
E Preferred Stock.
|
|
3.2
|
By-laws
of Registrant, as amended.
|
|
4.1
|
Specimen
certificate representing our Common Stock.
|
|
4.2
|
Rights
Agreement, dated as of November 19, 2002, between the Company and
Continental Stock Transfer & Trust Company. The Right Agreement
includes the Form of Certificate of Designation, Preferences and
Rights of
the Series A Junior Participating Preferred Stock, the Form of Rights
Certificate and the Summary of the Right to Purchase Preferred
Stock.(2)
|
|
4.3
|
Form
of 6% Convertible Debenture of the Company issued in March
2003.(1)
|
|
4.4
|
Form
of Warrant for Common Stock of the Company issued in March
2003.(1)
|
|
4.5
|
Form
of Warrant for Common Stock of the Company issued in June
2003.(3)
|
|
4.6
|
Form
of 6% Convertible Debenture of the Company issued in July
2003.(4)
|
|
4.7
|
Form
of Warrant for Common Stock of the Company issued in July
2003.(4)
|
|
4.8
|
Form
of 6% Convertible Debenture of the Company issued in October
2003.(5)
|
|
4.9
|
Form
of Warrant for Common Stock of the Company issued in October
2003.(5)
|
|
4.10
|
Form
of 6% Convertible Debenture of the Company issued in January
2004.(6)
|
|
4.11
|
Form
of Warrant for Common Stock of the Company issued in January
2004.(6)
|
|
4.12
|
Form
of Warrant for Common Stock of the Company. (9)
|
|
4.13
|
Amendment
Agreement, effective October 6, 2005, by and among the Company and
debenture holders.(11)
|
|
4.14
|
Form
of Series A amended 7% Convertible Debenture of the Company (amending
Debenture due October 31, 2005).(11)
|
|
4.15
|
Form
of Series B amended 7% Convertible Debenture of the Company (amending
Debenture issued on January 26, 2004 and due January 31,
2006).(11)
|
|
4.16
|
Form
of Series C amended 7% Convertible Debenture of the Company (amending
Debenture issued on July 13, 2004 and due January 31,
2006).(11)
|
|
4.17
|
Form
of Warrant issued effective October 6, 2005 for Common Stock of the
Company.(11)
|
|
5.1
|
Opinion
of Silverman Sclar Shin & Byrne PLLC, legal
counsel.*
|
|
10.1
|
1990
Stock Option Plan.
|
|
10.2
|
1992
Stock Option Plan.
|
|
10.3
|
1993
Employee Stock Purchase Plan.
|
|
10.4
|
Form
of Confidentiality, Invention and Non-Compete
Agreement.
|
|
10.5
|
Form
of Clinical Research Agreement.
|
|
10.6
|
Form
of Collaboration Agreement.
|
|
10.7
|
Amended
and Restated Employment Agreement by and between the Company and
Dr.
William A. Carter, dated as of July 1, 1993. (7)
|
|
10.8
|
Employment
Agreement by and between the Registrant and Robert E. Peterson, dated
April 1, 2001.
|
|
10.9
|
License Agreement by and between the Company and The Johns Hopkins University, dated December 31, 1980. |
|
10.10
|
Technology
Transfer, Patent License and Supply Agreement by and between the
Company,
Pharmacia LKB Biotechnology Inc., Pharmacia P-L Biochemicals Inc.
|
|
and
E.I. du Pont de Nemours and Company, dated November 24,
1987.
|
|
|
10.11
|
Pharmaceutical
Use Agreement, by and between the Company and Temple University,
dated
August 3, 1988.
|
|
10.12
|
Assignment
and Research Support Agreement by and between the Company, Hahnemann
University and Dr. David Strayer, Dr. lsadore Brodsky and Dr. David
Gillespie, dated June 30, 1989.
|
|
10.13
|
Lease
Agreement between the Company and Red Gate Limited Partnership, dated
November 1, 1989, relating to the Company's Rockville, Maryland
facility.
|
|
10.14
|
Agreement
between the Company and Bioclones (Proprietary)
Limited.
|
|
10.15
|
Amendment,
dated August 3, 1995, to Agreement between the Company and Bioclones
(Proprietary) Limited (contained in Exhibit 10.14).
|
|
10.16
|
Licensing
Agreement with Core BioTech Corp.
|
|
10.17
|
Licensing
Agreement with BioPro Corp.
|
|
10.18
|
Licensing
Agreement with BioAegean Corp.
|
|
10.22
|
Agreement
with Esteve.
|
|
10.23
|
Agreement
with Accredo (formerly Gentiva) Health Services.
|
|
10.24
|
Agreement
with Biovail Corporation International.
|
|
10.22
|
Forbearance
Agreement dated March 11, 2003, by and between ISI, the American
National
Red Cross and the Company.(1)
|
|
10.23
|
Forbearance
Agreement dated March 11, 2003, by and between ISI, GP Strategies
Corporation and the Company.(1)
|
|
10.24
|
Securities
Purchase Agreement, dated March 12, 2003, by and among the Company
and the
Buyers named therein.(1)
|
|
10.25
|
Registration
Rights Agreement, dated March 12, 2003, by and among the Company
and the
Buyers named therein.(1)
|
|
10.26
|
Securities
Purchase Agreement, dated July 10, 2003, by and among the Company
and the
Buyers named therein.(4)
|
|
10.27
|
Registration
Rights Agreement, dated July 10, 2003, by and among the Company and
the
Buyers named therein.(4)
|
|
10.28
|
Securities
Purchase Agreement, dated October 29, 2003, by and among the Company
and
the Buyers named therein.(5)
|
|
10.29
|
Registration
Rights Agreement, dated October 29, 2003, by and among the Company
and the
Buyers named therein.(5)
|
|
10.30
|
Securities
Purchase Agreement, dated January 26, 2004, by and among the Company
and
the Buyers named therein.(6)
|
|
10.31
|
Registration
Rights Agreement, dated January 26, 2004, by and among the Company
and the
Buyers named therein.(6)
|
|
10.32
|
Memorandum
of Understanding with Fujisawa. (8)
|
|
10.33
|
Securities
Purchase Agreement, dated July 30, 2004, by and among the Company
and the
Purchasers named therein.(9)
|
|
10.34
|
Registration
Rights Agreement, dated July 30, 2004, by and among the Company and
the
Purchasers named therein. (9)
|
|
10.35
|
Agreement
for services of R. Douglas Hulse, (12)
|
|
10.36
|
Amended
and Restated Employment Agreement of Dr. William A. Carter.
(10)
|
|
10.37
|
Engagement
Agreement with Dr. William A. Carter. (10)
|
|
10.38
|
Amended
and restated employment agreement of Dr. William A. Carter
(12)
|
|
10.39
|
Amended
and restated engagement agreement with Dr. William A. Carter
(12)
|
|
10.40
|
Amended
and restated engagement agreement with Robert E. Peterson
(12)
|
|
10.41
|
Engagement
Agreement with Ransom W. Etheridge (12)
|
|
10.42
|
Change
in control agreement with Dr. William A. Carter (12)
|
|
10.43
|
Change
in control agreement with Dr. William A. Carter (12)
|
|
10.44
|
Change
in control agreement with Robert E. Peterson (12)
|
|
10.45
|
Change
in control agreement with Ransom Etheridge (12)
|
|
10.46
|
Supply
Agreement with Hollister-Stier Laboratories LLC
|
|
10.47
|
Manufacturing
and Safety Agreement with Hyaluron, Inc.
|
|
10.48
|
Common
Stock Purchase Agreement, dated July 8, 2005, by and among the Company
and
Fusion Capital.(13)
|
|
10.49
|
Registration
Rights Agreement, dated July 8, 2005, by and among the Company and
Fusion
Capital.(13)
|
|
10.48
|
Common
Stock Purchase Agreement, dated April 12, 2006, by and among the
Company
and Fusion Capital.(14)
|
|
10.49
|
April
19, 2006 Amendment to Common Stock Purchase Agreement by and among
the
Company and Fusion Capital.
|
|
10.50
|
July
21, 2006 Letter Amendment to Common Stock Purchase Agreement by and
among
the Company and Fusion Capital.
|
|
10.51
|
Registration
Rights Agreement, dated April 12, 2006, by and among the Company
and
Fusion Capital.(14)
|
|
10.52
|
Royalty
Purchase Agreement with Stem Cell Innovations, Inc.
|
|
21
|
Subsidiaries
of the Registrant.
|
|
23.1
|
Consent
of BDO Seidman, LLP.**
|
|
23.2
|
Consent
of Silverman Sclar Shin & Byrne PLLC, legal counsel (included in
Exhibit 5.1).
|
|
24.1
|
Powers
of Attorney (included in Signature Pages to this Registration Statement
on
Form S-1).
|
|
*
|
Filed
herewith.
|
|
**
|
Previously
filed.
|
|
(1)
|
Filed
with the Securities and Exchange Commission as an exhibit to the
Company’s
Current Report on Form 8-K (No. 1-13441) dated March 12, 2003 and
is
hereby incorporated by reference.
|
|
(2)
|
Filed
with the Securities and Exchange Commission on November 20, 2002
as an
exhibit to the Company’s Registration Statement on Form 8-A (No. 0-27072)
and is hereby incorporated by
reference.
|
|
(3)
|
Filed
with the Securities and Exchange Commission as an exhibit to the
Company’s
Current Report on Form 8-K (No. 1-13441) dated June 27, 2003 and
is hereby
incorporated by reference.
|
|
(4)
|
Filed
with the Securities and Exchange Commission as an exhibit to the
Company’s
Current Report on Form 8-K (No. 1-13441) dated July 14, 2003 and
is hereby
incorporated by reference.
|
|
(5)
|
Filed
with the Securities and Exchange Commission as an exhibit to the
Company’s
Current Report on Form 8-K (No. 1-13441) dated October 30, 2003 and
is
hereby incorporated by reference.
|
|
(6)
|
Filed
with the Securities and Exchange Commission as an exhibit to the
Company’s
Current Report on Form 8-K (No. 1-13441) dated January 27, 2004 and
is
hereby incorporated by reference.
|
|
(7)
|
Filed
with the Securities and Exchange Commission as an exhibit to the
Company’s
quarterly report on Form 10-Q (No. 1-13441) for the period ended
September
30, 2001 and is hereby incorporated by
reference.
|
|
(8)
|
Filed
with the Securities and Exchange Commission as an exhibit to the
Company’s
Form S-1 Registration Statement (No. 333-113796) and is hereby
incorporated by reference.
|
|
(9)
|
Filed
with the Securities and Exchange Commission as an exhibit to the
Company’s
Current Report on Form 8-K (No. 1-13441) dated August 6, 2004 and
is
hereby incorporated by reference.
|
|
(10)
|
Filed
with the Securities and Exchange Commission as an exhibit to the
Company’s
Current Report on Form 8-K (No. 1-13441) dated September 15, 2004
and is
hereby incorporated by reference.
|
|
(11)
|
Filed
with the Securities and Exchange Commission as an exhibit to the
Company’s
Current Report on Form 8-K/A-1 (No. 1-13441) filed on October 28,
2005 and
is hereby incorporated by
reference.
|
|
(12)
|
Filed
with the Securities and Exchange Commission as an exhibit to the
Company’s
annual report on Form 10-K (No. 1-13441) for the year ended December
31,
2004 and is hereby incorporated by
reference.
|
|
(13)
|
Filed
with the Securities and Exchange Commission as an exhibit to the
Company’s
Current Report on Form 8-K (No. 1-13441) dated September 15, 2005
and is
hereby incorporated by reference.
|
|
(14)
|
Filed
with the Securities and Exchange Commission as an exhibit to the
Company’s
Current Report on Form 8-K (No. 1-13441) dated April 12, 2006 and
is
hereby incorporated by
reference.
|
| By: |
/s/William
A. Carter
William
A. Carter, M.D.,
Chief
Executive Officer
|
|
Signature
|
Title
|
Date
|
||
|
/s/William
A. Carter
|
Chairman
of the Board, Chief Executive Officer
|
|||
|
William
A. Carter, M.D.
|
(Principal
Executive) and Director
|
August
7, 2006
|
||
|
|
||||
|
*
|
Director
|
|||
|
Richard
C. Piani
|
|
August
7, 2006
|
||
|
*
|
Chief
Financial Officer and Chief Accounting Officer
|
|||
|
Robert
E. Peterson
|
|
August
7, 2006
|
||
|
*
|
Secretary,
General Counsel And Director
|
|||
|
Ransom
W. Etheridge
|
|
August
7, 2006
|
||
|
*
|
Director
|
|||
|
William
M. Mitchell, M.D., Ph.D.
|
|
August
7, 2006
|
||
|
*
|
Director
|
|||
|
Steven
D. Spence
|
|
August
7, 2006
|
||
|
*
|
Director
|
|||
|
Iraj-Eqhbal
Kiani, M.D.
|
|
August
7, 2006
|
| * By: |
/s/
William A. Carter
William
A. Carter, M.D.,
Attorney-in-Fact
|